PTAB challenges

Proceedings overview

Only one AIA trial proceeding has been filed against US patent 9060561. This proceeding, IPR2025-01030, was denied institution on procedural grounds, meaning no claims were formally reviewed or invalidated by the PTAB. This outcome generally strengthens the patent's defensive posture, as it has survived an IPR challenge without any claims being canceled.

IPR2025-01030 — REVELYST SALES LLC et al. v. Brainguard Technologies Inc.

• Type: Inter Partes Review
• Filed: 2025-07-09
• Status: Discretionary Denial (as of 2025-12-23). The PTAB declined to institute the IPR on procedural grounds, rather than on the merits of patentability.
• Judge panel: Information regarding the specific Administrative Patent Judges (APJs) on the panel for the institution decision for IPR2025-01030 is not publicly available in the provided patent text or typical public PTAB data feeds without deeper inquiry into the USPTO's Patent Trial and Appeal Board End-to-End (PTAB E2E) system for the specific case.
• Petition grounds: Specific claims challenged, prior art references, and statutory bases (§ 102 / § 103 / § 112) are not detailed in the provided information. To obtain this, one would need to access the petition for IPR2025-01030 via the PTAB E2E system.
• Institution decision: Denied (Discretionary Denial). The decision to deny institution was made by 2025-12-23, as indicated by the "last modified" date on the proceeding status. The reasoning for a discretionary denial typically involves factors such as parallel district court litigation, advanced stage of the litigation, or inefficient use of PTAB resources, as per relevant PTAB rules (e.g., Fintiv factors) or other procedural considerations. The provided information only indicates "Procedural" and "Discretionary Denial" without further detail on the panel's specific reasoning.
• Final Written Decision: Not applicable, as institution was denied.
• Settlement / termination: Not applicable, as institution was denied.
• Appeal: Not applicable, as institution was denied.
• Defensive value: The discretionary denial means the patent claims were not subjected to a full inter partes review on their merits. For a defendant, this means the patent owner's claims have not been weakened by this IPR. However, it also means the patent's validity against the specific prior art raised in the petition has not been affirmed, only that the PTAB chose not to hear the challenge for procedural reasons. A future IPR petition, if it overcomes the procedural hurdle, could still challenge the claims.

Strategic summary

Currently, none of the claims of US9060561 have been formally canceled or invalidated by a PTAB Final Written Decision. The single IPR filed, IPR2025-01030, resulted in a discretionary denial of institution, leaving all claims (1-20) as originally granted. This means that, as of today, May 19, 2026, all claims of US9060561 are considered SUSTAINED in the sense that they have not been successfully challenged at the PTAB. They remain UNTESTED on the merits of patentability in an IPR.

Regarding the estoppel landscape, since IPR2025-01030 was denied institution on discretionary grounds, it is unlikely that the petitioner, REVELYST SALES LLC et al., would be estopped under 35 U.S.C. § 315(e)(2) from raising the same or reasonably could have raised grounds in future litigation. Estoppel typically applies after a final written decision or a judgment in a civil action. Therefore, for a defendant currently being asserted against, the prior-art grounds that might have been raised in IPR2025-01030 are likely still available for use in district court or potentially in a new IPR petition if the procedural bar can be overcome.

There are no apparent pattern signals such as multiple IPRs filed by the same petitioner, aggressive PTAB appeals by the patent owner, or involvement of a defensive aggregator like Unified Patents, other than the mention of Unified Patents as the source for the PTAB case information.

Recommended next steps

• Since IPR2025-01030 was denied institution, there is no Final Written Decision to link to for claim invalidation. The patent claims remain active and ostensibly valid.
• No active IPR proceedings are pending for this patent that would involve trial-stage milestones.
• A defendant facing assertion of US9060561 should recognize that the patent's claims have not been formally tested and found patentable by the PTAB on the merits. While this denial avoids invalidation, it also means the patent has not been "hardened" by surviving a full IPR trial. A new IPR petition could be considered, potentially addressing the procedural grounds that led to the discretionary denial in IPR2025-01030. It would be crucial to understand the specific reasoning for the discretionary denial by accessing the full institution decision for IPR2025-01030 on the PTAB E2E system to assess how to avoid similar outcomes.